Res Pract Thromb Haemost. 2026 Oct 14;10(7):107015. doi: 10.1016/j.rpth.2026.107015. eCollection 2026 Oct.
ABSTRACT
BACKGROUND: Direct oral anticoagulants (DOACs) are increasingly used as alternatives to vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE) in patients with sickle cell disease (SCD). However, comparative evidence is limited to small observational studies, and prior frequentist meta-analyses may be unreliable due to sparse data and zero-event outcomes.
OBJECTIVES: This study aimed to compare the efficacy and safety of DOACs versus VKAs for VTE treatment in adults with SCD.
METHODS: We conducted a systematic review and Bayesian meta-analysis of studies comparing DOACs with VKAs in patients with SCD and VTE. PubMed, Embase, and CENTRAL were searched from inception to March 2026. Primary outcomes were recurrent VTE and major bleeding (MB). Bayesian random-effects models with weakly informative priors were used to estimate pooled odds ratios (ORs) with 95% credible intervals (CrIs). Posterior probabilities were derived using Hamiltonian Monte Carlo sampling.
RESULTS: Four retrospective studies including 271 patients (155 DOACs and 116 VKAs) were included. Recurrent VTE did not differ between groups (OR, 0.82; 95% CrI, 0.38-1.75), with a 67.1% posterior probability favoring DOACs, indicating equipoise. DOACs were associated with a significantly lower risk of MB (OR, 0.25; 95% CrI, 0.07-0.80), with a 99.2% probability of superiority. Between-study heterogeneity was low (τ = 0.15 for recurrent VTE; τ = 0.30 for MB).
CONCLUSION: DOACs demonstrate comparable efficacy to VKAs for preventing recurrent VTE in SCD, with a clinically meaningful reduction in MB. Given their safety profile and convenience, DOACs may be preferred; randomized trials are needed to confirm these findings.
PMID:43034677 | PMC:PMC13769079 | DOI:10.1016/j.rpth.2026.107015

